Nesta quinta-feira (17/11), a The Lancet Oncology, um das revistas acadêmicas mais importantes no cenário internacional, publicou reportagem sobre as perspectivas para a saúde com o início do terceiro mandato de Luiz Inácio Lula da Silva em 2023. Arthur Aguillar, diretor de políticas públicas do IEPS, concedeu entrevista para a jornalista Marcia Triunfol. Confira abaixo trecho da reportagem.
“For the more than 215 million people living in Brazil, the new year will bring changes and challenges. On Jan 1, 2023, Luiz Inácio Lula da Silva will be sworn in as president after a turbulent period, during which he was in prison for almost 2 years due to corruption charges in his previous two terms (2003–06 and 2007–11). The charges were later dismissed as the Supreme Court in Brazil declared that da Silva, known as Lula, did not have a fair trial and that there was no evidence to support the charges. In this new mandate, his third, Lula will run a country split in half, as the difference from the far-right candidate (and current president) Jair Messias Bolsonaro was only 2·1 million votes, which is around 1% of the Brazilian population. Moreover, this time Lula will succeed a president who was accused of having downplayed the COVID-19 pandemic and to whom building a strong Sistema Único de Saúde (SUS; the Brazilian health system), was not on the agenda”